Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy

Overview of attention for article published in Lung Cancer: Targets and Therapy, August 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#5 of 128)
High Attention Score compared to outputs of the same age (88th percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

So far, Altmetric has seen 1 news story.

1. After a 3-year follow-up to a phase 3 trial, the epidermal growth factor receptor-tyrosine kinase inhibitor osimertinib…